KALA | tickerfilter.com

Fundamental analysis

23%

Profitability 8%

Dept financing 25%

Liquidity 58%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-19.14%

1 Month

-44.84%

3 Months

-45.16%

6 Months

-29.57%

1 Year

-50.92%

2 Year

-73.02%

Key data

Stock price

$3.74

P/E Ratio

0.00

DAY RANGE

$3.67 - $4.10

EPS

-$9.71

52 WEEK RANGE

$3.67 - $11.20

52 WEEK CHANGE

-$49.53

MARKET CAP

26.263 M

YIELD

N/A

SHARES OUTSTANDING

4.608 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

0.71

PUBLIC FLOAT

AVERAGE 10 VOLUME

$51,364

AVERAGE 30 VOLUME

$26,777

Company detail

CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.

KALA - KALA BIO, Inc.